NCT06075368Active, not recruiting
Efficacy and Safety of GENOSS® SES in Patients With Acute Coronary Syndrome (GENOSS ACS)
A Prospective, Multicenter, Observational Study to Evaluate the Efficacy and Safety of GENOSS SES in Patients With Acute Coronary Syndrome
Source: ClinicalTrials.gov · Last updated 11 Feb 2026
Brief summary (registry, in English)
The objective of this study is to evaluate the efficacy and safety of the GENOSS SES in patients with acute coronary syndrome (ACS) in real-world pratice.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 757 (actual)
- First submitted
- 4 Oct 2023
- Start date
- 16 Mar 2020
- Primary completion date
- 31 Dec 2025
- Lead sponsor
- Genoss Co., Ltd.
- Diseases
- Coronary artery disease
- NCT number
- NCT06075368
What you commit to
- Study type: Observational
- Participants enrolled: 757
- From 16 Mar 2020 to the primary completion date, 31 Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Criteria the registry did not label
- \<Inclusion Criteria\>
- Patients of 19 and over
- Patients with acute coronary syndrome treated with GENOSS SES
- Participants who voluntarily decide to participate in this clinical trial, agree to the study protocol and clinical follow-up plan, and provide written informed consent as study participants.
- \<Exclusion Criteria\>
- Patients who are contraindicated in the use of heparin, aspirin, clopidogrel, sirolimus, cobalt chromium and contrast agents
- \- However, patients with hypersensitivity to contrast agents may be eligible if it can be controlled by steroids and pheniramine. Patients with known anaphylaxis are excluded
- Patients who are pregnant or planning to become pregnant
- Patients scheduled to undergo surgery requiring the discontinuation of antiplatelet agents within 12 months from registration.
- Patients with a life expectancy of less than 1 year
- Patients who presented with cardiogenic shock at admission and are predicted to have a low chance of survival based on medical judgment.
- Patients who have already received treatment with another DES (Drug Eluting Stent), BVS (Bioresorbable Vascular Scaffolds), or BMS (Bare Metal Stent) at the time of registration.
- Patients currently participating in a randomized controlled trial involving medical devices.
Age in the registry: 19 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Seoul National University Bundang Hospital Coordinator of this site? Confirm its status | Seongnam-si | South Korea | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.